Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Department of Bioengineering, Graduate School of Engineering, The University of Tokyo, Tokyo 113-0033, Japan.
J Control Release. 2023 Oct;362:278-296. doi: 10.1016/j.jconrel.2023.08.049. Epub 2023 Sep 1.
Vaccination is an innovative strategy for cancer treatment by leveraging various components of the patients' immunity to boost an anti-tumor immune response. Rationally designed nanoparticles are well suited to maximize cancer vaccination by the inclusion of immune stimulatory adjuvants. Also, nanoparticles might control the pharmacokinetics and destination of the immune potentiating compounds. Poly-γ-glutamic acid (γ-PGA) based nanoparticles (NPs), which have a natural origin, can be easily taken up by dendritic cells (DCs), which leads to the secretion of cytokines which ameliorates the stimulation capacity of T cells. The intrinsic adjuvant properties and antigen carrier properties of γ-PGA NPs have been the focus of recent investigations as they can modulate the tumor microenvironment, can contribute to systemic anti-tumor immunity and subsequently inhibit tumor growth. This review provides a comprehensive overview on the potential of γ-PGA NPs as antigen carriers and/or adjuvants for anti-cancer vaccination.
疫苗接种是一种利用患者免疫的各种成分来增强抗肿瘤免疫反应的癌症治疗创新策略。合理设计的纳米粒子非常适合通过包含免疫刺激性佐剂来最大限度地发挥癌症疫苗接种的作用。此外，纳米粒子还可以控制免疫增强化合物的药代动力学和作用部位。基于聚γ-谷氨酸（γ-PGA）的纳米粒子（NPs）具有天然来源，可被树突状细胞（DCs）轻易摄取，导致细胞因子的分泌，从而改善 T 细胞的刺激能力。γ-PGA NPs 的内在佐剂特性和抗原载体特性是最近研究的重点，因为它们可以调节肿瘤微环境，有助于全身抗肿瘤免疫，并随后抑制肿瘤生长。本综述全面概述了 γ-PGA NPs 作为抗原载体和/或佐剂用于抗癌疫苗接种的潜力。
